Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Dr. Wood on Family Histories and Genetic Counseling

June 5th 2012

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

Two Newer Breast Cancer Therapies Not Superior to Standard Paclitaxel, Study Suggests

June 5th 2012

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

Pilot Study Evaluates a Proposed Quality Measure for Family History Collection and Genetic Testing Referral

June 5th 2012

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Dr. Rugo on Paclitaxel Superiority in Advanced Breast Cancer

June 5th 2012

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Dr. Blackwell Discusses the T-DM1 EMILIA Trial

June 3rd 2012

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Antibody Drug Conjugate T-DM1 Improves PFS in HER2-Positive Breast Cancer

June 3rd 2012

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

CDX-011 Shows Promise in GPNMB-Positive Triple-Negative Breast Cancer

May 23rd 2012

CDX-011, a targeted therapy designed to treat patients with advanced breast cancer, appears to increase PFS in TNBC patients who have received multiple prior lines of therapy and express GPNMB.

Hereditary Breast and Ovarian Cancer: Which Patients Are at High Risk?

May 23rd 2012

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

Younger Age, Recent Surgery, and Lymphedema Influence Decision for Repeat Mammogram in Breast Cancer Survivors

May 23rd 2012

Breast cancer survivors who are younger, closer to the time of surgery, or have upper-extremity lymphedema may be less likely to undergo repeat mammography.

NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care

May 23rd 2012

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Celldex Announces Webcast of EMERGE Data

May 21st 2012

Celldex Therapeutics will present the interim results of a phase IIb study testing the efficacy of a new monoclonal antibody in patients with advanced breast cancer.

Premature Aromatase Inhibitor Discontinuation Is Common

May 17th 2012

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Dr. Spector Discusses Breast Cancer Heterogeneity

May 14th 2012

Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity

Is There a Best Adjuvant Chemotherapy Regimen for Breast Cancer?

May 11th 2012

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

Leading Researcher Sees Turning Point in Breast Cancer: An Interview With José Baselga, MD, PhD

May 10th 2012

In a six-week span, José Baselga, MD, PhD, notched a stunning series of milestones in breast cancer research that could potentially change practice in different subtypes of the disease.

Dr. Ellis on Heterogeneity Impacting Biomarker Efficacy

May 9th 2012

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

Long-Term Breast Cancer Patient Follow-Up Care: Money Well Spent?

May 8th 2012

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.

Identifying Appropriate Patients for HER2-Targeted Therapies

May 6th 2012

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Genetic Assessment of Breast and Ovarian Cancer Risk

April 30th 2012

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

Dr. Dixon Advises Against Mastectomies

April 26th 2012

Dr. J. Michael Dixon, from Western General Hospital, Scotland, Advises Against Mastectomies

NEXT PAGE
PREVIOUS PAGE
x